Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Diane George
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00566696CT.gov Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies | — | Completed | — | — | — |
NCT00118352CT.gov Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Juvenile Myelomonocytic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Alemtuzumab (this asset) | Diane George | P2 | BB · 65 |
| Cyclophosphamide | Masonic Cancer Center, University of Minnesota | P4 | BBB |
| Busulfanum | Masonic Cancer Center, University of Minnesota | P4 | BBB |
| Thiotepa | St. Jude Children's Research Hospital | P3 | BBB |
| Fludarabine | Children's Oncology Group | P3 | BB |
| Cyclosporin A | Case Comprehensive Cancer Center | P3 | BB |
| Nivestim | Masonic Cancer Center, University of Minnesota | P3 | BB |
| Tacrolimus | Masonic Cancer Center, University of Minnesota | P2 | BB |
| Rituximab | Masonic Cancer Center, University of Minnesota | P3 | BB |
+36 more in the Juvenile Myelomonocytic Leukemia cohort
Other indications for Alemtuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Relapsing-Remitting Multiple Sclerosis | — | P4 | BBB · 73 |
| Myelodysplastic/Myeloproliferative Neoplasm | — | P2 | BB · 71 |
| Chronic Myeloid Leukemia | — | P2/3 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Alemtuzumab in Juvenile Myelomonocytic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-human-rat-monoclonal-campath-1h-gamma1-chain-anti-human-antigen-cd52-disulfide-with-human-rat-monoclonal-campath-1h-light-chain-dimer-juvenile-myelomonocytic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →